Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Hydrochlorothiazide and squamous cell carcinoma

Braden O’Neill, Samantha Moe and Christina Korownyk
Canadian Family Physician February 2020, 66 (2) 116;
Braden O’Neill
Assistant Professor in the Department of Family and Community Medicine at the University of Toronto in Ontario.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Moe
Clinical Evidence Expert for the College of Family Physicians of Canada in Mississauga, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Korownyk
Associate Professor with the PEER Group in the Department of Family Medicine at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Does hydrochlorothiazide (HCTZ) increase the risk of squamous cell carcinoma (SCC)?

Bottom line

Observational data suggest an association between HCTZ and the risk of SCC. Risk appears to consistently increase with dose and duration of use (eg, 5 years increases risk 3 to 4 times). Baseline incidence of SCC is less than 0.1% annually. The same risk has not been established with thiazidelike diuretics. The benefit of switching from HCTZ to another agent should be weighed against the risk of changing medications.

Evidence

Evidence is statistically significant unless otherwise stated.

  • In a systematic review1 of 2 cohort and 7 case-control studies (N = 395 789), SCC was associated with taking thiazide diuretics (odds ratio [OR] of 1.9).

    • -Subgroup analysis found HCTZ and HCTZ combinations increased SCC risk (OR = 2.0), and long-term HCTZ use (≥ 4.5 years) was associated with higher risk (OR = 3.3).

    • -Limitations: potential unmeasured confounders; recall and detection bias; and multiple comparisons.

  • In a large case-control study,2 80 162 SCC cases in Denmark were matched with 1 603 345 controls.

    • -A cumulative HCTZ dose of 50 000 mg or greater (about 6 years’ use) was associated with SCC risk (OR = 4.0).

    • -A consistent dose-response relationship was observed for SCC (OR = 7.4) with a cumulative HCTZ dose of 200 000 mg or greater (about 20 years’ use).

  • Use of HCTZ is associated with risk of SCC of the lip3:

    • -A dose-response effect was observed (OR = 7.7) with a cumulative dose of 100 000 mg or greater.

  • Another systematic review4 reported no effect with thiazides but did not include studies of HCTZ alone.

  • Increased risk of basal cell carcinoma is very small (OR = 1.2 to 1.3), if real.1,2

Context

  • Baseline SCC risk varies with ethnicity, age, sex, and location. A recent UK cohort study reported an incidence of 77 cases per 100 000 (< 0.1%) per year.5 Metastatic SCC developed in 1.1% to 2.4% of SCC patients.6

  • Non-randomized studies might overestimate beneficial and harmful effects and cannot prove causation.

  • Thiazide and thiazidelike agents reduce morbidity and mortality in RCTs and are recommended as first-line therapy in hypertension.7

  • One hypertension society recommends thiazidelike diuretics as the preferred initial option for hypertension, although it suggests continuing HCTZ in stable patients.8

Implementation

Physicians might counsel patients about the potentially small increased risk of SCC from baseline with HCTZ. Patients already at increased risk might want to avoid HCTZ. Patients taking HCTZ should be counseled about surveillance for new or changing moles and sun safety. Thiazidelike diuretics are an option and appear at least as good or better than HCTZ for blood pressure and clinical outcomes.9 Side effects such as electrolyte abnormalities should be considered. Online cardiovascular risk calculators might assist in reviewing the benefits of hypertension treatment and aid in shared informed decision making.10

Notes

Tools for Practice articles in Canadian Family Physician are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in Canadian Family Physician are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • Competing interests

    None declared

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de février 2020 à la page e53.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Shin D,
    2. Lee ES,
    3. Kim J,
    4. Guerra L,
    5. Naik D,
    6. Prida X
    . Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies. J Clin Med Res 2019;11(4):247-55.
    OpenUrl
  2. 2.↵
    1. Pedersen SA,
    2. Gaist D,
    3. Schmidt SAJ,
    4. Hölmich LR,
    5. Friis S,
    6. Pottegård A
    . Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol 2018;78(4):673-81.e9.
    OpenUrl
  3. 3.↵
    1. Pottegård A,
    2. Hallas J,
    3. Olesen M,
    4. Svendsen MT,
    5. Habel LA,
    6. Friedman GD,
    7. et al
    . Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017;282(4):322-31.
    OpenUrl
  4. 4.↵
    1. Gandini S,
    2. Palli D,
    3. Spadola G,
    4. Bendinelli B,
    5. Cocorocchio E,
    6. Stanganelli I,
    7. et al
    . Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018;122:1-9.
    OpenUrl
  5. 5.↵
    1. Venables ZC,
    2. Nijsten T,
    3. Wong KF,
    4. Autier P,
    5. Broggio J,
    6. Deas A,
    7. et al
    . Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013–15: a cohort study. Br J Dermatol 2019;181(3):474-82.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Venables ZC,
    2. Autier P,
    3. Nijsten T,
    4. Wong KF,
    5. Langan SM,
    6. Rous B,
    7. et al
    . Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England. JAMA Dermatol 2019;155(3):298-306.
    OpenUrl
  7. 7.↵
    1. Wright JM,
    2. Musini VM,
    3. Gill R
    . First-line drugs for hypertension. Cochrane Database Syst Rev 2018;(4):CD001841.
  8. 8.↵
    1. Faconti L,
    2. Ferro A,
    3. Webb AJ,
    4. Cruickshank JK,
    5. Chowienczyk PJ,
    6. British and Irish Hypertension Society
    . Hydrochlorothiazide and the risk of skin cancer. J Hum Hypertens 2019;33(4):257-8.
    OpenUrl
  9. 9.↵
    1. Allan GM,
    2. Ivers N,
    3. Padwal RS
    . Best thiazide diuretic for hypertension. Can Fam Physician 2012;58:653.
    OpenUrlFREE Full Text
  10. 10.↵
    1. McCormack J,
    2. Pfiffner P
    . The absolute CVD risk/benefit calculator. Vancouver, BC: Best Science Medicine; 2017. Available from: http://chd.bestsciencemedicine.com/calc2.html. Accessed 2019 Nov 13.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (2)
Canadian Family Physician
Vol. 66, Issue 2
1 Feb 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hydrochlorothiazide and squamous cell carcinoma
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hydrochlorothiazide and squamous cell carcinoma
Braden O’Neill, Samantha Moe, Christina Korownyk
Canadian Family Physician Feb 2020, 66 (2) 116;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Hydrochlorothiazide and squamous cell carcinoma
Braden O’Neill, Samantha Moe, Christina Korownyk
Canadian Family Physician Feb 2020, 66 (2) 116;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • L’hydrochlorothiazide et le carcinome épidermoïde
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
Show more Practice

Tools for Practice

  • Risk of muscle symptoms while taking statins
  • The value of family medicine
  • Bronchodilators or inhaled corticosteroids for postinfectious cough
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire